1グループ肺高血圧における高出力心不全の病理生理学と罹患率
Yogesh N V Reddy1, Robert P Frantz2, William R Miranda2
1The Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota Reddy.Yogesh@mayo.edu.
The European respiratory journal
|February 19, 2026
まとめ
1群肺高血圧 (PH) の患者の約10人に1人は,高心電量 (CO) 状態を発症し,しばしば血管拡張剤の使用の増加と関連しています. この高出力状態は,不良な心筋の再構築と死亡リスクの増加と関連しています.
科学分野:
- 心臓病学 心臓病学
- 肺高血圧の研究について
- ヘモダイナミクス (血動力学)
背景:
- 肺血管拡張剤は,グループ1の肺高血圧 (PH) で心電量 (CO) を増加させることができます.
- この患者集団における高COの影響を完全に理解していない.
- 高COの病理生理学を理解することは,治療の最適化に不可欠です.
研究 の 目的:
- グループ1の肺高血圧 (PH) の高心電量 (CO) の病理生理学を説明する.
- PH患者の異なるレベルのCOに関連した臨床的特徴とアウトカムを調査する.
主な方法:
- グループ1PH参加者449人のコホート (PVDOMICS) は,低,正常,または高心指数 (CI) によって分類されました.
- 臨床的特徴,血管拡張剤の使用,および血液動力学的パラメータは,グループ間で比較されました.
- 死亡率と移植率を含むアウトカムが分析されました.
主要な成果:
- 参加者の9%は高CO状態で,密集的な血管拡張剤の使用と低肺血管抵抗 (PVR) と関連していました.
- 高濃度のCO2は,心臓の改造 (左心室と左心房の拡大) と心筋の労働量の増加と関連していた.
- 酸素の供給が増加したにもかかわらず,周辺の酸素利用は低下し,正常出力PHと比較して生存の利益はありませんでした.
結論:
- 高出力状態は,グループ1PH患者の約10%に影響し,しばしば血管拡張器の強度に関連しています.
- この状態は,不良な心臓の改造と心筋の作業量の増加によって特徴付けられます.
- 血管拡張剤の投与量を最適化し,ソタテレセプトのような新しい治療法との相互作用を探求するためにさらなる研究が必要です.
関連する概念動画
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Pulmonary Hypertension: Classification and Pathogenesis
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...